Neodopaston combination tablets L100 (YJ code: 1169101F1120, standard: 1 tablet) are manufactured by Ohara Pharmaceutical. This medication combines levodopa, converted to dopamine in the brain, and carbidopa, which prevents levodopa’s peripheral breakdown, to treat Parkinson’s disease and parkinsonian syndrome.
Neodopaston combination tablets L100
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).
More with the same ingredient
